Potential Synergy Activity of the Novel Ceragenin, CSA-13, against Carbapenem-Resistant Acinetobacter baumannii Strains Isolated from Bacteremia Patients

Basit Öğe Kaydı
dc.authoridAlper Akçalı/0000-0003-0325-886X
dc.contributor.authorBozkurt-Guzel, Cagla
dc.contributor.authorSavage, Paul B.
dc.contributor.authorAlper Akçalı
dc.contributor.authorOzbek-Celik, Berna
dc.date.accessioned2025-01-27T20:45:42Z
dc.date.available2025-01-27T20:45:42Z
dc.date.issued2014
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractCarbapenem-resistant Acinetobacter baumannii is an important cause of nosocomial infections, particularly in patients in the intensive care units. As chronic infections are difficult to treat, attempts have been made to discover new antimicrobials. Ceragenins, designed to mimic the activities of antimicrobial peptides, are a new class of antimicrobial agents. In this study, the in vitro activities of CSA-13 either alone or in combination with colistin (sulphate), tobramycin, and ciprofloxacin were investigated using 60 carbapenem-resistant A. baumannii strains isolated from bacteremia patients blood specimens. MICs and MBCs were determined by microbroth dilution technique. Combinations were assessed by using checkerboard technique. The MIC50 values (mg/L) of CSA-13, colistin, tobramycin, and ciprofloxacin were 2, 1, 1.25, and 80, respectively. The MIC90 (mg/L) of CSA-13 and colistin were 8 and 4. The MBCs were equal to or twice greater than those of the MICs. Synergistic interactions were mostly seen with CSA-13-colistin (55%), whereas the least synergistic interactions were observed in the CSA-13-tobramycin (35%) combination. No antagonism was observed. CSA-13 appears to be a good candidate for further investigations in the treatment of A. baumannii infections. However, future studies should be performed to correlate the safety, efficacy, and pharmacokinetic parameters of this molecule.
dc.description.sponsorshipResearch Fund of Istanbul University [BYP 27662]
dc.description.sponsorshipThis work was supported by a grant from the Research Fund of Istanbul University (Project no. BYP 27662).
dc.identifier.doi10.1155/2014/710273
dc.identifier.issn2314-6133
dc.identifier.issn2314-6141
dc.identifier.pmid24804236
dc.identifier.scopus2-s2.0-84899500584
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.1155/2014/710273
dc.identifier.urihttps://hdl.handle.net/20.500.12428/24690
dc.identifier.volume2014
dc.identifier.wosWOS:000333912500001
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherHindawi Ltd
dc.relation.ispartofBiomed Research International
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20250125
dc.subjectMolecular Epidemiology
dc.subjectAntimicrobial Activity
dc.subjectSurveillance
dc.subjectSpread
dc.subjectAgents
dc.titlePotential Synergy Activity of the Novel Ceragenin, CSA-13, against Carbapenem-Resistant Acinetobacter baumannii Strains Isolated from Bacteremia Patients
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu